BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Peter Rehse Joins BioFocus DPI as Senior Director, Structural Biology


2/11/2013 12:16:33 PM

Saffron Walden, UK (11 February 2013) - BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK. His responsibilities will include managing the structural biology and fragment-based screening groups within the Biological Sciences division.

Peter joins BioFocus from the Chinese CRO Shanghai Medicilon Inc., where, as Vice President, he was responsible for the strategic business and scientific development of the structural biology and structure-based drug design unit. Prior to this Peter worked at RIKEN Harima Institute, in Japan and has held several academic positions in Japan and Canada. Peter studied for his PhD under the supervision of Professor Tom Blundell at the University of London and undertook post-doctoral research at the Max-Planck Institute.

“With Peter’s international credibility we will be able to strengthen and grow our structural biology and fragment screening operation,” commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus. “This hire reflects our ongoing commitment to accelerate our client’s discovery programs through investing in the right people."

Contacts:

Media enquiries

Katie Odgaard

Zyme Communications:

Tel: +44 7787 502 947

Email: katie.odgaard@zymecommunications.com

At BioFocus

Chris Newton

Managing Director

Tel: +44 1799 533 500

Email: chris.newton@glpg.com

About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capabilities in neurodegenerative diseases, inflammatory diseases and rare and neglected diseases. BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and pre-clinical candidates. The company employs over 150 exceptionally qualified and industry experienced scientists at its research centers in the UK and the Netherlands. Since its foundation in 1997, BioFocus has produced high quality data for its clients, assured by ISO9001 qualification, validated by regular independent inspection of all BioFocus research centers. More information can be found at www.biofocus.com.

BioFocus® is a trademark of Galapagos NV and/or its affiliates © Copyright 2013 Galapagos NV.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES